CRISPR Therapeutics–Needham: investor conference, 201704 supply service CRISPR Therapeutics presents at Annual Needham Healthcare Conference in NY

	Period	2017-04-05
	Region	New York, NY
	Country	United States (USA)
	Partner, 1st	CRISPR Therapeutics AG (Nasdaq: CRSP)
	Group	CRISPR Therapeutics (Group)
	Partner, 2nd	Needham & Company, LLC
	Group	Needham (Group)
	Product	Needham & Company 16th Annual Healthcare Conference 2017 New York
	Product 2	CRISPR gene editing technology
	Person	Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
	Person 2	Paganelli, Jennifer (W2O Group 201703)

CRISPR Therapeutics AG. (3/30/17). "Press Release: CRISPR Therapeutics to Present at the 16th Annual Needham Healthcare Conference". Basel & Cambridge, MA.

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Dr. Sam Kulkarni, Chief Business Officer of CRISPR Therapeutics, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5th at the Westin Grand Central Hotel, New York, NY.

Event: 16th Annual Needham Healthcare Conference

Date: Wednesday, April 5th

Time: 12:50-1:30 PM ET

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at www.crisprtx.com.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.

MEDIA CONTACTS:
Jennifer Paganelli
WCG for CRISPR
347-658-8290 jpaganelli@wcgworld.com

INVESTOR CONTACT:
Chris Brinzey
Westwicke Partners for CRISPR
339-970-2843 chris.brinzey@westwicke.com